followup to stanjupiter's excellent post

Thank you stanjupiter for a very informed, thoughtful and important post. As a scientist who has worked in a number of areas including the gut and immune area I can only strongly support the points regarding GI permeability, perils of broad immune suppression and the need to interface with thoughtful, multidisciplinary clinical organisations whose reputations will give them clout in the US and Europe. I’m hoping the CEO and Board are reading and taking seriously stanjupiter’s post. It is more than time to fight fire with fire. If big pharma are playing the brutal game to hamstring MSB based on its financial situation, then we should be employing a well connected, proven, hardnosed business executive who can approach a range of highly successful, cashed up technology companies, outside our industry, aggressively looking to diversify and who don’t carry the baggage and conflict of interest of those within the pharma industry.